Filgotinib as rheumatoid arthritis therapy
Copyright 2021 Clarivate Analytics..
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to maintain a good response over time. The recent introduction of Janus kinase inhibitors (JAKis) has widened the rheumatologist's armamentarium. Filgotinib, a selective JAK1 inhibitor, has been approved by the European Medicines Agency (EMA) for treatment of RA. Phase II and III studies highlighted filgotinib safety and efficacy in RA patients naive to DMARDs or with inadequate response to csDMARDs and bDMARDs. Filgotinib is administered orally at 200 mg every day. For patients older than 75 years or with moderate to severe renal impairment, a dose of filgotinib 100 mg every day is recommended.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 57(2021), 9 vom: 01. Sept., Seite 543-550 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Becciolini, A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.10.2021 Date Revised 01.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2021.57.9.3317241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331276291 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331276291 | ||
| 003 | DE-627 | ||
| 005 | 20231225213116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2021.57.9.3317241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331276291 | ||
| 035 | |a (NLM)34586102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Becciolini, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Filgotinib as rheumatoid arthritis therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.10.2021 | ||
| 500 | |a Date Revised 01.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2021 Clarivate Analytics. | ||
| 520 | |a Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to maintain a good response over time. The recent introduction of Janus kinase inhibitors (JAKis) has widened the rheumatologist's armamentarium. Filgotinib, a selective JAK1 inhibitor, has been approved by the European Medicines Agency (EMA) for treatment of RA. Phase II and III studies highlighted filgotinib safety and efficacy in RA patients naive to DMARDs or with inadequate response to csDMARDs and bDMARDs. Filgotinib is administered orally at 200 mg every day. For patients older than 75 years or with moderate to severe renal impairment, a dose of filgotinib 100 mg every day is recommended | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoimmune disorders | |
| 650 | 4 | |a Filgotinib | |
| 650 | 4 | |a Janus kinase 1 (JAK1) inhibitors | |
| 650 | 4 | |a Musculoskeletal and connective tissue disorders | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Tyrosine kinase inhibitors | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a GLPG0634 |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 700 | 1 | |a Di Donato, E |e verfasserin |4 aut | |
| 700 | 1 | |a Santilli, D |e verfasserin |4 aut | |
| 700 | 1 | |a Lucchini, G |e verfasserin |4 aut | |
| 700 | 1 | |a Mozzani, F |e verfasserin |4 aut | |
| 700 | 1 | |a Riva, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ariani, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 57(2021), 9 vom: 01. Sept., Seite 543-550 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g number:9 |g day:01 |g month:09 |g pages:543-550 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2021.57.9.3317241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |e 9 |b 01 |c 09 |h 543-550 | ||